Search hospitals

>

California

>

Los Angeles

Cedars-Sinai Medical Center

Claim this profile

Los Angeles, California 90048

Global Leader in Breast Cancer

Global Leader in Cancer

Conducts research for Pancreatic Cancer

Conducts research for Lung Cancer

Conducts research for Solid Tumors

1450 reported clinical trials

171 medical researchers

Photo of Cedars-Sinai Medical Center in Los AngelesPhoto of Cedars-Sinai Medical Center in Los AngelesPhoto of Cedars-Sinai Medical Center in Los Angeles

Summary

Cedars-Sinai Medical Center is a medical facility located in Los Angeles, California. This center is recognized for care of Breast Cancer, Cancer, Pancreatic Cancer, Lung Cancer, Solid Tumors and other specialties. Cedars-Sinai Medical Center is involved with conducting 1,450 clinical trials across 1,611 conditions. There are 171 research doctors associated with this hospital, such as Leo Mascarenhas, MD, Fataneh (Fae) Majlessipour, Saibal Kar, MD, and Raj Makkar.

Area of expertise

1

Breast Cancer

Global Leader

Cedars-Sinai Medical Center has run 105 trials for Breast Cancer. Some of their research focus areas include:

Stage IV
HER2 negative
ER positive
2

Cancer

Global Leader

Cedars-Sinai Medical Center has run 97 trials for Cancer. Some of their research focus areas include:

Stage IV
Stage III
Stage I

Top PIs

Clinical Trials running at Cedars-Sinai Medical Center

Breast Cancer

Lung Cancer

Skin Cancer

Breast cancer

Crohn's Disease

Kidney Cancer

Non-Hodgkin's Lymphoma

Ovarian Cancer

Cancer

Testicular cancer

Image of trial facility.

RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant

for Breast Cancer

This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutation following recurrence or progression on or after treatment with a CDK4/6 inhibitor.

Recruiting

2 awards

Phase 3

5 criteria

Image of trial facility.

Low Dose Tamoxifen

for Breast Cancer

This phase III trial compares the effect of low dose tamoxifen to usual hormonal therapy, including aromatase inhibitors, in treating post-menopausal women with hormone positive, HER2 negative early stage breast cancer. Tamoxifen is in a class of medications known as antiestrogens. It blocks the activity of estrogen (a female hormone) in the breast. This may stop the growth of some breast tumors that need estrogen to grow. Aromatase inhibitors, such as anastrozole, letrozole, and exemestane, prevent the formation of estradiol, a female hormone, by interfering with an aromatase enzyme. Aromatase inhibitors are used as a type of hormone therapy to treat postmenopausal women with hormone-dependent breast cancer. Giving low dose tamoxifen may be more effective compared to usual hormone therapy in treating post-menopausal women with hormone-positive, HER2 negative early stage breast cancer.

Recruiting

2 awards

Phase 3

8 criteria

Image of trial facility.

Shorter Chemo-Immunotherapy Without Anthracyclines

for Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.

Recruiting

2 awards

Phase 3

47 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Cedars-Sinai Medical Center?

Where is Cedars-Sinai Medical Center located?

Who should I call to ask about financial aid or insurance network?

What insurance does Cedars-Sinai Medical Center accept?

What awards or recognition has Cedars-Sinai Medical Center received?